Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year